Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases.

Pokryszka, Jagoda; Wagner, Angelika; Wiedermann, Ursula; Tobudic, Selma; Herkner, Harald; Winkler, Stefan; Brehovsky, Sonja; Reinisch, Walter; Novacek, Gottfried

Pokryszka, Jagoda; Wagner, Angelika; Wiedermann, Ursula; Tobudic, Selma; Herkner, Harald; Winkler, Stefan; Brehovsky, Sonja; Reinisch, Walter; Novacek, Gottfried.

Afiliação

Pokryszka J; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090 Vienna, Austria.
Wagner A; Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Wiedermann U; Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Tobudic S; Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Herkner H; Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Winkler S; Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Brehovsky S; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090 Vienna, Austria.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090 Vienna, Austria.
Novacek G; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090 Vienna, Austria.